三氧化二砷、沙利度胺和地塞米松联合治疗复发性、难治性多发性骨髓瘤  

Combination of Arsenic Trioxide,Thalidomide and Dexamethasone in Treatment for Relapsed and Refractory Multiple Myeloma

作　　者：胡致平[1] 林圣云[1] 罗秀素[1] 沈一平[1] 沈建平[1] 郑智茵[1] 陈均法[1] 叶宝东[1] 周郁鸿[1] 虞荣喜[1] 

机构地区：[1]浙江中医药大学附属医院浙江省中医院,浙江杭州310006

出　　处：《中国肿瘤》2007年第2期131-133,共3页China Cancer

摘　　要：[目的]探索治疗复发性、难治性多发性骨髓瘤(MM)的有效方法。[方法]经传统化疗方案和干扰素等治疗后复发、再次治疗困难或无效的MM患者共45例,给予三氧化二砷(As2O3)10mg/d,静脉滴注,第1～28天;地塞米松(DXM)40mg/d,第1～4、9～12、17～20、25～28天;沙利度胺(THL)200mg/d,第1～28天。每4周1个疗程,休息4周,连用2个疗程评价疗效。[结果]95.6%(43/45)患者均有效,其中37.8%(17/45)获PR,57.8%(26/45)获有效。6个月无进展生存率(PFS)和12个月PFS分别为89.3%和73.2%。大部分患者都有不同程度的水钠潴留症状,均未见明显骨髓抑制。[结论]三氧化二砷、沙利度胺和地塞米松联合方案是治疗复发性、难治性MM的有效并安全的方法。[Purpose ] To explore effective approach for the relapsed and refractory multiple myeloma（MM）. [Methods ] Forty-five cases who had been relapsing after or refractory to the conventional chemotherapy and interferon-α treatments were enrolled. ATD regimen was given, including arsenic trioxide（ATO） 10mg/d intravenously on days 1 to 28, Dexamethasone（DXM）40 mg/d, d1～4, 9～12,17～20,25～28;thalidomide（THL） 200 mg/d, d 1～28. Every 4 weeks was a cycle, and the cycle repeated every 8 weeks. The efficacy was evaluated after 2 cycles. [Results ] There was 95.6% （43/45） cases responded, with 37.8%（17/45） partial remission（PR）. Six-months＇ and 12-months＇ progress free survival（PFS） were 89.3% and 73.2% respectively. Severe bone marrow toxicity was not found. Hyperglycemia and edema were found in most of the patients. [Conclusions ] ATD regimen is effective and safe for refractory and relapsed MM.

关 键 词：多发性骨髓瘤 三氧化二砷 沙利度胺 地塞米松 

分 类 号：R733.3[医药卫生—肿瘤]